Evidence map›Paper›PMID 24999799›Full record

Trial reportJournal of hypertension2014

Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial.

Toshio Ogihara, Takao Saruta, Hiromi Rakugi, Ikuo Saito, Kazuaki Shimamoto, Hiroaki Matsuoka, Kazuyuki Shimada, Sadayoshi Ito, Masatsugu Horiuchi, Tsutomu Imaizumi and 14 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of hypertension, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 9 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 9 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Calcium channel blockers versus other classes of drugs for hypertension.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Calcium channel blockers versus other classes of drugs for hypertension.The Cochrane database of systematic reviews · 2021
    Pooled it
  3. Pooled it
  4. Guideline
  5. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).Hypertension research : official journal of the Japanese Society of Hypertension · 2019
    Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Elucidating the complex interplay between chronic kidney disease and hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Review
  16. Management of Hypertension in the Asia-Pacific Region: A Structured Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 17 institutions in 1 country.

Toshio OgiharaaMorinomiya University of Medical Sciences, Osaka bKeio University, Tokyo cOsaka University Graduate School of Medicine, Osaka dSapporo Medical University, Hokkaido eDokkyo Medical University fShin-Oyama City Hospital, Tochigi gTohoku University Graduate School of Medicine, Miyagi hEhime University Graduate School of Medicine, Ehime iKurume University School of Medicine, Fukuoka jUniversity of the Ryukyus School of Medicine, Okinawa kSaitama Medical University, Saitama lAsahi Rousai Hospital, Aichi mYokohama City University Graduate School of Medicine, Kanagawa nSapporo Nishimaruyama Hospital, Hokkaido oTokyo Medical University, Tokyo pKawasaki Medical School, Okayama qKanazawa University Hospital, Ishikawa, Japan.
Takao Saruta
Hiromi Rakugi
Ikuo Saito
Kazuaki Shimamoto
Hiroaki Matsuoka
Kazuyuki Shimada
Sadayoshi Ito
Masatsugu Horiuchi
Tsutomu Imaizumi
Shuichi Takishita
Jitsuo Higaki
Shigehiro Katayama
Genjiroh Kimura
Satoshi Umemura
Nobuyuki Ura
Koichi Hayashi
Masato Odawara
Norio Tanahashi
Toshihiko Ishimitsu
Naoki Kashihara
Satoshi Morita
Satoshi Teramukai
COLM Investigators
Keio University · JPDokkyo Medical University · JPEhime University · JPSaitama Medical University · JPYokohama City University · JPKanazawa University · JPKawasaki Medical School · JPKurume University · JPMorinomiya University of Medical Sciences · JPNagasaki Rousai Hospital · JPNaruto, Tokushima Prefecture hospital · JPOsaka University · JPSapporo Medical University · JPTohoku University · JPTokyo Medical University · JPUniversity of the Ryukyus · JPYamato Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of the present study was to compare the cardiovascular effects of olmesartan, an angiotensin II receptor blocker, combined with a calcium channel blocker (CCB) or a diuretic, in a prospective, randomized, open-label, blinded endpoint trial.

methodsJapanese hypertensive patients aged at least 65 to less than 85 years with SBP at least 140 mmHg and/or DBP at least 90 mmHg with antihypertensive treatment, or SBP at least 160 mmHg and/or DBP at least 100 mmHg without antihypertensive treatment were randomized to receive olmesartan with either a dihydropyridine CCB or a low-dose diuretic. If SBP and/or DBP remained at least 140 and/or at least 90 mmHg, the other antihypertensive drug was added. The primary endpoint was a composite of fatal and nonfatal cardiovascular events. The median follow-up time was 3.3 years.

resultsBlood pressure decreased similarly in both groups. The primary endpoint occurred in 116/2568 patients (4.5%) in the olmesartan plus CCB group and in 135/2573 patients (5.3%) in the olmesartan plus diuretic group [hazard ratio 0.83, 95% confidence interval (CI) 0.65-1.07, P = 0.16]. Rates of all-cause death and cardiovascular deaths were similar. Among patients aged at least 75 years, the incidence of stroke tended to be lower in the olmesartan plus CCB group than in the olmesartan plus diuretic group (hazard ratio 0.63, 95% CI 0.38-1.02, P = 0.059, interaction P = 0.019). Fewer patients in the olmesartan plus CCB group (8.2%, 211/2568) than in the olmesartan plus diuretic group (9.8%, 253/2573; P = 0.046) experienced serious adverse events.

conclusionDespite no significant difference in cardiovascular events, the different safety profiles suggest that the combination of olmesartan and CCB may be preferable to that of olmesartan and diuretic.

Indexed as

AgedAged, 80 and overAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsBlood PressureCalcium Channel BlockersDiureticsDrug Therapy, CombinationFemaleHumansHypertensionImidazolesIncidenceJapanMaleProspective StudiesAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsCalcium Channel BlockersDiureticsImidazolesolmesartanTetrazoles

Identifiers

PMID24999799
PMCPMC4166009
OpenAlexW2050003957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.